RecruitingNCT05117125

Biomarkers for Ventilator-associated Pneumonia

Biomarkers for Prediction of and Diagnosis of Ventilator-associated Pneumonia


Sponsor

Region Skane

Enrollment

1,000 participants

Start Date

Oct 15, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to evaluate different peptide biomarkers, variations in the microbiome and patterns in the bacterial transcriptome as prognostic or diagnostic biomarkers of VAP.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study collects samples from the airways of ICU patients who are on mechanical ventilators to look for biological markers (biomarkers) that can predict who will develop ventilator-associated pneumonia (VAP) — a serious lung infection that can occur when patients are on breathing machines. Early identification of patients at risk could allow doctors to intervene sooner and potentially save lives. You may be eligible if... - You have been admitted to an intensive care unit - You were intubated (placed on a breathing machine) within the last 24 hours - You are expected to need mechanical ventilation for at least 48 hours You may NOT be eligible if... - You require very high levels of oxygen (FiO2 above 70%) or very high ventilator pressure (PEEP above 15) - You have a severe blood clotting problem - You already have a lung infection at the time of ICU admission - You have severely elevated or unstable pressure inside your skull Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTHeparin-binding protein

Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.

DIAGNOSTIC_TESTInterleukin-26

Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.

DIAGNOSTIC_TESTMicrobiome

Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.

DIAGNOSTIC_TESTBacterial transcriptome

Evaluation of the specificity and sensitivity of the bacterial transcriptome as prognostic biomarker for treatment failure of VAP.

DIAGNOSTIC_TESTProteome

Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.


Locations(5)

Vestre Viken

Drammen, Norway

Hospital de São Francisco Xavier

Lisbon, Portugal

Skåne University Hospital, Dept. of Infectious diseases

Lund, Sweden

Skåne university Hospital, ICU

Malmö, Sweden

Karolinska University Hospital, ICU

Solna, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05117125


Related Trials